Our top pick for
EyeGate Pharmaceuticals, Inc is a biotechnology business based in the US. EyeGate Pharmaceuticals shares (EYEG) are listed on the NASDAQ and all prices are listed in US Dollars. EyeGate Pharmaceuticals employs 14 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$3.20 - $7.85|
|50-day moving average||$4.86|
|200-day moving average||$4.91|
|Wall St. target price||$13.08|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.27|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$-3,553,986|
|Return on assets TTM||-38.58%|
|Return on equity TTM||-118.81%|
|Market capitalisation||$29.1 million|
TTM: trailing 12 months
There are currently 2,186 EyeGate Pharmaceuticals shares held short by investors – that's known as EyeGate Pharmaceuticals's "short interest". This figure is 82.1% down from 12,195 last month.
There are a few different ways that this level of interest in shorting EyeGate Pharmaceuticals shares can be evaluated.
EyeGate Pharmaceuticals's "short interest ratio" (SIR) is the quantity of EyeGate Pharmaceuticals shares currently shorted divided by the average quantity of EyeGate Pharmaceuticals shares traded daily (recently around 18216.666666667). EyeGate Pharmaceuticals's SIR currently stands at 0.12. In other words for every 100,000 EyeGate Pharmaceuticals shares traded daily on the market, roughly 120 shares are currently held short.
However EyeGate Pharmaceuticals's short interest can also be evaluated against the total number of EyeGate Pharmaceuticals shares, or, against the total number of tradable EyeGate Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case EyeGate Pharmaceuticals's short interest could be expressed as 0% of the outstanding shares (for every 100,000 EyeGate Pharmaceuticals shares in existence, roughly 0 shares are currently held short) or 0.0004% of the tradable shares (for every 100,000 tradable EyeGate Pharmaceuticals shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against EyeGate Pharmaceuticals.
Find out more about how you can short EyeGate Pharmaceuticals stock.
We're not expecting EyeGate Pharmaceuticals to pay a dividend over the next 12 months.
EyeGate Pharmaceuticals's shares were split on a 1:15 basis on 29 August 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your EyeGate Pharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for EyeGate Pharmaceuticals shares which in turn could have impacted EyeGate Pharmaceuticals's share price.
Over the last 12 months, EyeGate Pharmaceuticals's shares have ranged in value from as little as $3.2 up to $7.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while EyeGate Pharmaceuticals's is 1.2195. This would suggest that EyeGate Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
EyeGate Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop, which is in Phase I safety study for multiple diseases that affect the ocular surface and anterior region of the eye, comprising of allergic conjunctivitis, viral conjunctivitis, and dry eye disease. The company also develops ocular bandage gel, a modified form of the natural polymer hyaluronic acid for corneal wound repair, and punctate epitheliopathies with a focus on dry eye. The company has license agreements with BioTime, Inc. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.